Is the Assumption of Treatment Waning Applied Consistently Across Canada’s Drug Agency Reimbursement Reviews? Reviewing Pharmacoeconomic Assessments of Disease Modifying Therapies for the Treatment of Multiple Sclerosis

Previous PostAssessing the Acceptance of Single-Arm Trials in Health Technology Appraisals: A Review of NICE, CADTH, HAS, and NCPE Appraisals in 2024
Next PostNovel Therapies for Neurofibromatosis Type 1-Associated Inoperable Plexiform Neurofibromas: A Systematic Literature Review

© Copyright 2025 Initiate Consultancy is a limited company.
Registered in England and Wales. Reg No. 11903774 | Privacy Policy

Let’s discuss your purpose

hello@initiateconsultancy.com